home / stock / esalf / esalf quote
Last: | $41.075 |
---|---|
Change Percent: | 5.03% |
Open: | $41.075 |
Close: | $41.075 |
High: | $41.075 |
Low: | $41.075 |
Volume: | 930 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$41.075 | $41.075 | $41.075 | $41.075 | $41.075 | 930 | 07-02-2024 |
$43.25 | $0 | $43.25 | $0 | $0 | 23 | 07-01-2024 |
$43.25 | $43.25 | $43.25 | $43.25 | $43.25 | 189 | 06-28-2024 |
$39.12 | $0 | $39.12 | $0 | $0 | 13 | 06-27-2024 |
$39.12 | $0 | $39.12 | $0 | $0 | 720 | 06-26-2024 |
$39.12 | $39.12 | $39.12 | $39.12 | $39.12 | 208 | 06-25-2024 |
$40 | $38.15 | $40 | $40 | $38.15 | 497 | 06-24-2024 |
$38.4 | $0 | $38.4 | $0 | $0 | 15 | 06-21-2024 |
$38.4 | $38.4 | $38.4 | $38.4 | $38.4 | 306 | 06-20-2024 |
$39.18 | $39.18 | $39.18 | $39.18 | $39.18 | 100 | 06-19-2024 |
$39.18 | $39.18 | $39.18 | $39.18 | $39.18 | 100 | 06-18-2024 |
$39.56 | $0 | $39.56 | $0 | $0 | 10 | 06-17-2024 |
$39.56 | $40.1 | $39.56 | $40.1 | $39.26 | 11,435 | 06-14-2024 |
$40.62 | $40.62 | $40.62 | $40.62 | $40.62 | 1,092 | 06-12-2024 |
$42.815 | $0 | $42.815 | $0 | $0 | 30 | 06-11-2024 |
$42.815 | $0 | $42.815 | $0 | $0 | 18 | 06-10-2024 |
$42.815 | $43 | $42.815 | $43 | $42.805 | 800 | 06-07-2024 |
$43 | $44.13 | $43 | $44.13 | $42.66 | 500 | 06-06-2024 |
$44.9 | $44.9 | $44.9 | $44.9 | $44.9 | 1,000 | 06-05-2024 |
$44.21 | $44.21 | $44.21 | $44.21 | $44.21 | 1,850 | 06-04-2024 |
News, Short Squeeze, Breakout and More Instantly...
Eisai Co Ltd Company Name:
ESALF Stock Symbol:
OTCMKTS Market:
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) TOKYO, July 2, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squi...
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China TOKYO and CAMBRIDGE, Mass., June 28, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that the humanized anti-soluble aggregated amyloid-beta (Abeta) monoclo...
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City TOKYO, June 21, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company has achieved the pre-set performance indicators in FY2023 for the dementia examination project in Bunkyo Cit...